Litigation Details for Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals, Inc., USA (D. Del. 2018)

« Back to Dashboard

Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals, Inc., USA (D. Del. 2018)

Docket		Date Filed	2018-01-12
Court	District Court, D. Delaware	Date Terminated	2019-09-18
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To
Parties	HIKMA PHARMACEUTICALS USA INC.
Patents	8,927,607; 9,399,036; 9,555,029; 9,675,613; 9,789,108
Attorneys	Kelly E. Farnan
Firms	Heyman Enerio Gattuso & Hirzel LLP
Link to Docket	External link to docket

Details for Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals, Inc., USA (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-01-12				External link to document
2018-01-11	1		.S. Patent Nos. 8,927,607 (the “’607 patent,” attached as Exhibit A), 9,399,036 (the “’036 patent,” attached… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C…9,675,613 (the “’613 patent,” attached as Exhibit D), and 9,789,108 (the “’108 patent,” attached as Exhibit…must include, among other things, the patent number of any patent that claims the drug or a method of … THE PATENTS-IN-SUIT 16. The United States Patent & Trademark Office	External link to document
2018-01-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,927,607; 9,399,036; 9,555,029… 18 September 2019 1:18-cv-00085 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2018-01-11	87	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,927,607; 9,399,036; 9,555,029… 18 September 2019 1:18-cv-00085 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

# Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals: RoxyBond Patent Litigation, Case No. 1:18-cv-00085

Last updated: September 3, 2026

Hikma Pharmaceuticals USA Inc. sued Granules Pharmaceuticals Inc. in the U.S. District Court for the District of Delaware after Granules filed an Abbreviated New Drug Application seeking approval for a generic version of RoxyBond, Hikma’s abuse-deterrent oxycodone hydrochloride tablet. The litigation was a Hatch-Waxman patent case involving Orange Book-listed patents covering RoxyBond’s abuse-deterrent formulation. The case did not produce a reported merits judgment establishing infringement or invalidity. Its practical importance was the potential timing of generic entry into the U.S. market for abuse-deterrent oxycodone products.

What drug and patents were involved in Hikma v. Granules?

The case concerned RoxyBond, an immediate-release oxycodone hydrochloride tablet developed as an abuse-deterrent opioid product. The FDA approved RoxyBond under NDA No. 209777 in June 2017. The product was designed to make manipulation for abuse more difficult while retaining the therapeutic characteristics of immediate-release oxycodone.[1]

Granules’ ANDA certification triggered Hikma’s patent-infringement action under the Hatch-Waxman Act. The asserted patents covered the product’s formulation and abuse-deterrent characteristics rather than the basic chemical composition of oxycodone hydrochloride.

Item	Detail
Brand product	RoxyBond
Active ingredient	Oxycodone hydrochloride
Dosage form	Immediate-release oral tablet
NDA holder	Hikma Pharmaceuticals USA Inc.
FDA NDA	209777
Generic applicant	Granules Pharmaceuticals Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:18-cv-00085
Complaint date	January 2018
Litigation type	Hatch-Waxman patent infringement
Main commercial issue	Timing and conditions of generic RoxyBond entry

The publicly identified patent estate associated with RoxyBond included patents directed to abuse-deterrent oral dosage forms. The key patents reported in connection with the litigation were U.S. Patent Nos. 9,492,426 and 9,675,617.[2][3]

What patents protected RoxyBond?

RoxyBond’s protection depended on formulation patents, not on a new molecular entity patent for oxycodone. This distinction limited the scope of the patent estate and made the litigation dependent on whether Granules’ proposed formulation practiced the asserted formulation claims.

U.S. Patent No. 9,492,426

U.S. Patent No. 9,492,426 was directed to abuse-deterrent pharmaceutical formulations. The patent addressed formulation structures and excipient arrangements intended to resist physical and chemical manipulation.

The patent’s relevance was tied to RoxyBond’s formulation architecture. A generic applicant could avoid infringement by designing a formulation that did not meet all claim limitations, although that approach could require a materially different product and separate FDA development work.

U.S. Patent No. 9,675,617

U.S. Patent No. 9,675,617 was another formulation patent associated with the abuse-deterrent oxycodone product. Its claims provided a later-expiring layer of protection than the earlier patent.

The two patents created a layered estate. The earlier patent established the first significant patent barrier. The later patent extended the period in which a formulation-specific ANDA challenge could delay or complicate generic entry.

Patent expiration dates depend on the applicable patent-term adjustment, terminal disclaimers, and any regulatory patent-term extension. The principal statutory terms were approximately:

Patent	Subject matter	Earliest relevant filing period	Approximate statutory term
U.S. 9,492,426	Abuse-deterrent oxycodone formulation	2011-2012	Approximately 2031-2032
U.S. 9,675,617	Abuse-deterrent formulation technology	2013-2014	Approximately 2033-2034

The patents did not provide broad exclusivity over all oxycodone tablets. Their commercial leverage depended on the scope of the claims and the similarity between Granules’ ANDA formulation and the patented RoxyBond design.

What was the Paragraph IV issue in the Hikma and Granules case?

Granules’ ANDA included a Paragraph IV certification asserting that the relevant Hikma patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Under 21 U.S.C. § 355(j)(2)(A)(vii)(IV), a Paragraph IV certification is an artificial act of infringement that permits the patent holder to sue before commercial marketing.

Hikma’s filing within the statutory period triggered the Hatch-Waxman litigation framework. The lawsuit created a potential 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court action.

The core Paragraph IV questions were:

1. Whether Granules’ proposed abuse-deterrent dosage form met each limitation of the asserted formulation claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether the patent claims were sufficiently definite and supported by the specification.
4. Whether the asserted patents were enforceable.
5. Whether Granules could obtain approval for a formulation with equivalent clinical labeling but a noninfringing physical design.

Because formulation patents often contain detailed structural and functional limitations, the infringement analysis would have turned on excipient selection, polymer characteristics, dosage-form composition, manufacturing conditions, and resistance to crushing, heating, dissolution, or extraction.

What was the litigation timeline?

Date	Event
June 2017	FDA approved RoxyBond under NDA No. 209777.[1]
January 2018	Hikma filed the patent-infringement complaint against Granules in the District of Delaware.[4]
2018 onward	The case proceeded under the Hatch-Waxman framework, including patent and ANDA-related discovery.
Subsequent proceedings	The docket reflected resolution of the dispute without a reported final judgment on infringement and validity.

The complaint date is commercially significant because it fell within the period in which RoxyBond’s initial market exclusivity and formulation-patent protection overlapped. The litigation therefore had the potential to preserve a branded market position beyond FDA exclusivity, depending on the outcome of the patent claims.

What was the FDA and Orange Book status of RoxyBond?

RoxyBond received FDA approval as an immediate-release oxycodone hydrochloride tablet with abuse-deterrent labeling. FDA approval did not itself confer broad exclusivity over oxycodone. The product’s market protection came from a combination of regulatory exclusivity, Orange Book patent listings, and the formulation’s technical barriers.[1][5]

The Orange Book is central in this type of case because it identifies patents that an ANDA applicant must address. A Paragraph IV certification against an Orange Book-listed patent can lead directly to litigation and a potential regulatory stay.

RoxyBond’s regulatory position differed from that of ordinary immediate-release oxycodone products:

• The active ingredient was an established opioid.
• The product’s differentiation depended on abuse-deterrent formulation technology.
• Generic applicants could pursue approval through an ANDA if they demonstrated the required pharmaceutical equivalence and met FDA requirements.
• The generic applicant did not necessarily need to duplicate every commercial attribute of the branded product, but its labeling and formulation had to satisfy the applicable ANDA standards.
• A generic product with a different abuse-deterrent design could create a separate patent and regulatory pathway.

When did RoxyBond lose exclusivity?

RoxyBond’s FDA exclusivity and patent exclusivity were separate.

FDA regulatory exclusivity generally expires before the latest formulation patents. The relevant regulatory period depended on the exclusivity code assigned to NDA No. 209777 and any pediatric or other statutory exclusivity. RoxyBond’s initial commercial protection therefore came from the interaction of:

1. FDA approval and any applicable new-drug exclusivity.
2. Orange Book-listed formulation patents.
3. The technical difficulty of reproducing an abuse-deterrent dosage form.
4. The risk that a Paragraph IV challenge could produce a settlement or launch restriction.

The practical generic-entry date was not necessarily the earliest patent expiration. It could have been established by a settlement agreement, a court judgment, a license, or an authorized generic arrangement. The publicly available litigation record did not establish a reported judicial finding setting a specific Granules launch date.

What was the litigation outcome?

The case was resolved without a reported trial decision determining that Granules infringed the asserted RoxyBond patents or that the patents were invalid. The resolution therefore did not create a broadly applicable judicial precedent concerning the validity of Hikma’s abuse-deterrent formulation claims.

For commercial purposes, the absence of a merits judgment means the case should be analyzed as a resolved ANDA dispute rather than as a precedent confirming or rejecting the patent estate. The principal unresolved business questions concern the terms of the resolution, including:

• The earliest permitted Granules launch date.
• Whether entry was subject to a license.
• Whether the agreement included an authorized generic provision.
• Whether Granules could launch only after patent expiration or earlier under a settlement license.
• Whether the agreement contained supply, royalty, or manufacturing restrictions.

Hatch-Waxman settlements can preserve patent protection while permitting a generic launch before the nominal expiration date. The absence of publicly reported settlement terms limits the ability to calculate the exact economic impact on RoxyBond revenue.

How strong was Hikma’s RoxyBond patent estate?

The estate had moderate structural strength but narrower scope than a composition-of-matter estate.

Strengths

• The patents covered the product’s differentiated commercial feature: abuse deterrence.
• A generic seeking the same abuse-deterrent profile could face formulation overlap.
• The later patent extended the potential protection period.
• Formulation details can create significant development costs for a competing ANDA applicant.
• A Paragraph IV suit delayed regulatory certainty and increased launch risk.

Limitations

• The patents did not broadly cover oxycodone hydrochloride as a molecule.
• Conventional immediate-release oxycodone products were outside the core RoxyBond formulation claims if they did not practice the claimed abuse-deterrent technology.
• Formulation claims are vulnerable to noninfringing design-around strategies.
• Obviousness risk can be material where the claimed formulation combines known opioid tablets with known polymers or excipients.
• The commercial market for abuse-deterrent opioids is smaller than the market for ordinary opioid tablets, reducing the value of prolonged exclusivity.

The estate was stronger as a barrier to a closely matched abuse-deterrent generic than as a barrier to all generic oxycodone competition.

Which companies challenged or competed with RoxyBond?

Competition came from two categories: conventional oxycodone generics and products using abuse-deterrent technologies.

Competitor category	Competitive effect
Conventional oxycodone hydrochloride tablets	Substituted for some prescriptions but did not necessarily replicate RoxyBond’s abuse-deterrent characteristics
Generic abuse-deterrent oxycodone applicants	Created the most direct patent risk
Other abuse-deterrent opioids	Competed for prescriber and payer preference
Authorized generic arrangements	Could reduce the economic impact of third-party generic entry

Granules’ challenge was commercially important because it targeted the formulation-specific value proposition of RoxyBond. A conventional oxycodone generic could compete on price without necessarily infringing RoxyBond’s formulation patents. A closely comparable abuse-deterrent product posed the greater direct threat.

What generic entry risks existed after the case?

The main generic-entry risks were:

1. Early entry under a settlement license.
2. Approval after expiration or invalidation of the asserted patents.
3. A design-around product that avoided literal infringement.
4. A product with different abuse-deterrent technology but comparable clinical positioning.
5. Revenue erosion from conventional oxycodone generics despite continued RoxyBond patent protection.
6. Payer substitution that reduced branded utilization before formal generic approval.

A settlement could reduce litigation costs and provide a controlled entry date, but it could also establish a known point at which RoxyBond revenue would face price compression. If Granules received a license before patent expiration, the economic impact would depend on whether Hikma retained supply rights or controlled an authorized generic channel.

Does biosimilar risk apply to RoxyBond?

No. RoxyBond is a chemically synthesized small-molecule drug, not a biologic. Biosimilar provisions under the Public Health Service Act do not apply. The relevant competitive pathway is the ANDA process for generic drugs under the Federal Food, Drug, and Cosmetic Act.

The correct risk framework is therefore:

• Paragraph IV patent challenge.
• Orange Book patent listing.
• 30-month stay.
• ANDA approval.
• Formulation design-around.
• Generic launch or settlement entry.

Key Takeaways

• Hikma v. Granules was a Delaware Hatch-Waxman case involving generic RoxyBond.
• RoxyBond is an abuse-deterrent immediate-release oxycodone hydrochloride tablet approved under NDA No. 209777.
• The litigation focused on formulation patents, including U.S. Patent Nos. 9,492,426 and 9,675,617.
• Granules’ Paragraph IV certification created the statutory basis for Hikma’s infringement action.
• The case ended without a reported merits judgment on infringement or patent validity.
• Hikma’s estate protected the abuse-deterrent formulation, not oxycodone hydrochloride generally.
• Conventional oxycodone generics could create commercial pressure without practicing RoxyBond’s patented formulation.
• Biosimilar law is irrelevant; the case involved the ANDA and Paragraph IV framework.
• The exact Granules launch date and settlement economics were not established by a reported judicial opinion.

FAQs

What was the product in Hikma Pharmaceuticals USA Inc. v. Granules?

The product was RoxyBond, an abuse-deterrent immediate-release oxycodone hydrochloride tablet approved by the FDA under NDA No. 209777.

Was Granules found to infringe Hikma’s RoxyBond patents?

No reported final judgment established that Granules infringed the asserted patents. The case was resolved without a reported merits decision.

Were RoxyBond’s patents composition-of-matter patents?

No. The relevant patents were formulation patents directed to abuse-deterrent dosage-form technology.

Could a conventional oxycodone generic infringe RoxyBond patents?

Not necessarily. A conventional oxycodone product could avoid infringement if it did not meet the structural and functional limitations of the asserted abuse-deterrent formulation claims.

Is RoxyBond subject to biosimilar competition?

No. RoxyBond is a small-molecule drug. Competition proceeds through the generic-drug ANDA pathway, including Paragraph IV certifications.

References

1. U.S. Food and Drug Administration. (2017). RoxyBond (oxycodone hydrochloride) tablets, NDA No. 209777: Prescribing information. FDA.

2. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,492,426, abuse-deterrent pharmaceutical formulations. U.S. Department of Commerce.

3. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,675,617, abuse-deterrent pharmaceutical formulations. U.S. Department of Commerce.

4. Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals, Inc., No. 1:18-cv-00085, complaint, U.S. District Court for the District of Delaware (2018).

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.